Dose Equivalence and Safety Considerations for Risperidone ↔ Olanzapine

Elderly Patients with Dementia‑Related Psychosis

The maximum recommended dose of risperidone in this population is 2–3 mg per day to limit adverse events【1】.
Initiation of olanzapine should start at 2.5–5 mg daily, with heightened caution because of the FDA black‑box warning for increased mortality in dementia‑related psychosis【3】.
Both antipsychotics carry substantial safety risks in older adults, making strict dose‑equivalence calculations less clinically relevant than adherence to these safety thresholds【3】.

In first‑episode schizophrenia, risperidone doses should not exceed 4 mg per day; a dose of 2 mg is considered a reasonable mid‑range starting point【1】.

Extrapyramidal symptoms (EPS): Risperidone at 2 mg/day is associated with a higher EPS risk, especially in elderly patients【3】.
EPS (Olanzapine): Olanzapine at the equivalent dose (≈7.5 mg) demonstrates a lower EPS risk compared with risperidone【2】.
Metabolic effects: Olanzapine 7.5 mg carries a greater propensity for weight gain and metabolic syndrome than risperidone 2 mg, warranting routine metabolic monitoring【2】.
Sedation: Olanzapine is more sedating; the 7.5 mg dose is typically administered at bedtime to mitigate daytime drowsiness【3】.

When converting a patient from risperidone 2 mg to olanzapine, start olanzapine at 7.5 mg at bedtime and cross‑taper both agents over 1–2 weeks, closely observing for symptom recurrence or new adverse effects【3】.